These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21220252)

  • 61. β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations.
    Mersfelder TL; Shiltz DL
    Ann Pharmacother; 2019 Dec; 53(12):1249-1258. PubMed ID: 31271049
    [No Abstract]   [Full Text] [Related]  

  • 62. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).
    Duffy S; Marron R; Voelker H; Albert R; Connett J; Bailey W; Casaburi R; Cooper JA; Curtis JL; Dransfield M; Han MK; Make B; Marchetti N; Martinez F; Lazarus S; Niewoehner D; Scanlon PD; Sciurba F; Scharf S; Reed RM; Washko G; Woodruff P; McEvoy C; Aaron S; Sin D; Criner GJ;
    Respir Res; 2017 Jun; 18(1):124. PubMed ID: 28629419
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial.
    Sundh J; Magnuson A; Montgomery S; Andell P; Rindler G; Fröbert O;
    Trials; 2020 Jan; 21(1):123. PubMed ID: 32000825
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease.
    Neef PA; Burrell LM; McDonald CF; Irving LB; Johnson DF; Steinfort DP
    Intern Med J; 2017 Sep; 47(9):1043-1050. PubMed ID: 28608512
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease.
    Neef PA; McDonald CF; Burrell LM; Irving LB; Johnson DF; Steinfort DP
    Intern Med J; 2016 Nov; 46(11):1336-1340. PubMed ID: 27813357
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.
    Petta V; Perlikos F; Loukides S; Bakakos P; Chalkias A; Iacovidou N; Xanthos T; Tsekoura D; Hillas G
    Heart Fail Rev; 2017 Nov; 22(6):753-763. PubMed ID: 28840400
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Beta Adrenergic Blocker Use in Patients With Chronic Obstructive Pulmonary Disease and Concurrent Chronic Heart Failure With a Low Ejection Fraction.
    Mtisi TF; Frishman WH
    Cardiol Rev; 2020; 28(1):20-25. PubMed ID: 31804289
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Beta-Blockers in COPD: A Methodological Review of the Observational Studies.
    Suissa S; Ernst P
    COPD; 2018 Oct; 15(5):520-525. PubMed ID: 30822238
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Objective criteria for assessing benefits of therapy in COPD - ATS/ERS guidelines 2007].
    Cuvelier A; Roche N
    Rev Mal Respir; 2007 Sep; 24(7):827-9. PubMed ID: 17925664
    [No Abstract]   [Full Text] [Related]  

  • 70. [New GOLD guidelines for the therapy of COPD].
    Hausen T
    Pneumologie; 2012 Dec; 66(12):768. PubMed ID: 23225409
    [No Abstract]   [Full Text] [Related]  

  • 71. [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].
    Karoli NA; Rebrov AP
    Kardiologiia; 2021 Oct; 61(10):89-98. PubMed ID: 34763643
    [TBL] [Abstract][Full Text] [Related]  

  • 72. COPD: Optimizing treatment.
    Ahmed-Sarwar N; Pierce DP; Holub DC
    J Fam Pract; 2015 Oct; 64(10):610-23. PubMed ID: 26551477
    [No Abstract]   [Full Text] [Related]  

  • 73. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.
    Gulea C; Zakeri R; Alderman V; Morgan A; Ross J; Quint JK
    Respir Res; 2021 Feb; 22(1):64. PubMed ID: 33622362
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The place of β-adrenoblockers in the treatment of cardiovascular disease in patients with chronic obstructive pulmonary disease].
    Statsenko ME; Derevianchenko MV
    Kardiologiia; 2012; 52(12):57-63. PubMed ID: 23237442
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Beta-blockers and obstructive pulmonary diseases: such an odd couple?].
    Grosgurin O; Bria A; Gaspoz JM
    Rev Med Suisse; 2006 Jan; 2(50):285-8. PubMed ID: 16503045
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials.
    Ni Y; Shi G; Wan H
    J Int Med Res; 2012; 40(6):2051-65. PubMed ID: 23321161
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Should we treat chronic obstructive pulmonary disease as a cardiovascular disease?
    Rabinovich RA; MacNee W
    Expert Rev Respir Med; 2015 Aug; 9(4):459-72. PubMed ID: 26190174
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.
    Andrus MR; Loyed JV
    Drugs Aging; 2008; 25(2):131-44. PubMed ID: 18257600
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Beta-blockers and chronic obstructive pulmonary disease].
    Sova M; Kamasová M; Václavík J; Sovová E; Hajdová L; Kolek V
    Vnitr Lek; 2016 Apr; 62(4):305-7. PubMed ID: 27250608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Obstructive lung diseases and beta-blockers: Where do we stand?
    Pité H; da Cruz MB; Morais-Almeida M
    Eur J Intern Med; 2016 Oct; 34():e32-e33. PubMed ID: 27179413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.